Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer.

CD44v6 CellSearch® cancer stem cells circulating tumor cells colorectal cancer

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
10 Nov 2020
Historique:
received: 22 07 2020
accepted: 17 10 2020
entrez: 23 11 2020
pubmed: 24 11 2020
medline: 24 11 2020
Statut: epublish

Résumé

CD44v6, the CD44 isoform mostly involved in cancer cell migration and invasion, has been identified as a functional biomarker and therapeutic target in colon cancer stem cells. We here provide evidence that baseline CD44v6-positive CTC predict treatment failure in patients with metastatic colorectal cancer undergoing first-line chemotherapy. We suggest that CD44v6-positive CTC can be used to early detect intrinsic drug resistance in this cancer type.

Identifiants

pubmed: 33227095
doi: 10.18632/oncotarget.27794
pii: 27794
pmc: PMC7665234
doi:

Types de publication

Journal Article

Langues

eng

Pagination

4115-4122

Informations de copyright

Copyright: © 2020 Nicolazzo et al.

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Références

Oncotarget. 2017 Dec 22;9(70):33403-33415
pubmed: 30279970
Cell Stem Cell. 2020 Apr 2;26(4):569-578.e7
pubmed: 32169167
Cell Death Dis. 2019 Jan 10;10(1):30
pubmed: 30631039
Sci Rep. 2016 Aug 24;6:31726
pubmed: 27553175
Breast Cancer Res Treat. 2020 May;181(1):61-68
pubmed: 32200486
Gut. 2018 Jun;67(6):1103-1111
pubmed: 28360095
Clin Cancer Res. 2010 Nov 1;16(21):5233-43
pubmed: 20978147
Sci Rep. 2018 Oct 29;8(1):15931
pubmed: 30374140
Expert Rev Mol Med. 2017 Mar 21;19:e3
pubmed: 28322181
J Gastrointest Cancer. 2008;39(1-4):73-8
pubmed: 19333790
Cell Stem Cell. 2014 Mar 6;14(3):342-56
pubmed: 24607406
J Cell Mol Med. 2010 Aug;14(8):2073-7
pubmed: 20597995
Sci Rep. 2020 Jan 28;10(1):1288
pubmed: 31992773
J Clin Oncol. 2008 Apr 20;26(12):2006-12
pubmed: 18421053
Cell Death Differ. 2006 Mar;13(3):465-77
pubmed: 16167069
Methods Mol Biol. 2019;1884:247-258
pubmed: 30465208
Int J Colorectal Dis. 2013 Jan;28(1):9-18
pubmed: 22733437
J Cancer Res Clin Oncol. 2013 Aug;139(8):1411-6
pubmed: 23736274
Gut. 2017 Oct;66(10):1802-1810
pubmed: 27456153
Cancers (Basel). 2019 Apr 05;11(4):
pubmed: 30959764
N Engl J Med. 2009 Apr 2;360(14):1408-17
pubmed: 19339720
Tumori. 2013 Jan-Feb;99(1):88-92
pubmed: 23549006
Tumour Biol. 2016 Jul;37(7):8811-24
pubmed: 26747179
Blood. 2009 Dec 10;114(25):5236-44
pubmed: 19773544

Auteurs

Chiara Nicolazzo (C)

Department of Molecular Medicine, Liquid Biopsy Unit, Sapienza University of Rome, Rome, Italy.

Flavia Loreni (F)

Department of Molecular Medicine, Liquid Biopsy Unit, Sapienza University of Rome, Rome, Italy.

Salvatore Caponnetto (S)

Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.

Valentina Magri (V)

Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.

Anna Rita Vestri (AR)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Rita Zamarchi (R)

Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

Angela Gradilone (A)

Department of Molecular Medicine, Liquid Biopsy Unit, Sapienza University of Rome, Rome, Italy.

Antonella Facchinetti (A)

Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.

Elisabetta Rossi (E)

Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.

Enrico Cortesi (E)

Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.

Paola Gazzaniga (P)

Department of Molecular Medicine, Liquid Biopsy Unit, Sapienza University of Rome, Rome, Italy.

Classifications MeSH